QUBIT PHARMACEUTICALS : revenue, balance sheet and financial ratios

QUBIT PHARMACEUTICALS is a French company founded 6 years ago, specialized in the sector Conseil en systèmes et logiciels informatiques. Based in PARIS (75014), this company of category PME shows in 2024 a revenue of 187 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - QUBIT PHARMACEUTICALS (SIREN 883649238)
Indicator 2024 2023 2022
Revenue 187 318 € 76 727 € N/C
Net income -795 896 € -133 389 € -884 141 €
EBITDA -2 611 515 € -1 453 632 € -1 109 662 €
Net margin -424.9% -173.8% N/C

Revenue and income statement

En 2024, QUBIT PHARMACEUTICALS alcanza unos ingresos de 187 k€. En el período 2023-2024, la empresa muestra un fuerte crecimiento con una TCAC de +144.1%. Vs 2023, crecimiento de +144% (77 k€ -> 187 k€). Tras deducir el consumo (0 €), el margen bruto se sitúa en 187 k€, es decir, una tasa del 100%. El EBITDA alcanza -2.6 M€, representando el -1394.2% de los ingresos. Efecto tijera positivo: el margen EBITDA mejora en +500.4 puntos. Un EBITDA negativo significa que las operaciones no cubren los gastos corrientes. El resultado neto es negativo en -796 k€ (-424.9% de los ingresos).

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

187 318 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

187 318 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-2 611 515 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-3 255 269 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

-795 896 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

-1346.9%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

El ratio de endeudamiento (= Deuda financiera / Fondos propios x 100) se sitúa en 86%. El nivel de deuda es alto: el margen de negociación con los bancos se reduce. La autonomía financiera (= Fondos propios / Total activo x 100) alcanza el 49%. Esta alta autonomía significa que la empresa financia la mayoría de sus activos con fondos propios.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

86.433%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

48.987%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

-157.625%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

-44.175

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

37.7%

Solvency indicators evolution
QUBIT PHARMACEUTICALS

Sector positioning

Ratio de endeudamiento
86.43 2024
2022
2023
2024
Q1: 0.0
Med: 3.93
Q3: 32.58
Average +25 pts over 3 years

En 2024, el ratio de endeudamiento de QUBIT PHARMACEUTICALS (86.43) se sitúa por encima de la mediana del sector. Este ratio mide el peso de la deuda en relación con el patrimonio. Un esfuerzo de reducción podría mejorar la solidez financiera.

Autonomía financiera
48.99% 2024
2022
2023
2024
Q1: 7.97%
Med: 34.38%
Q3: 62.44%
Bueno -12 pts over 3 years

En 2024, el autonomía financiera de QUBIT PHARMACEUTICALS (49.0%) se sitúa por encima de la mediana del sector. Este ratio representa la parte del patrimonio en la financiación total. Esta posición cómoda ofrece un margen de seguridad apreciable.

Capacidad de reembolso
-44.17 ans 2024
2022
2023
2024
Q1: 0.0 ans
Med: 0.0 ans
Q3: 0.5 ans
Excelente

En 2024, el capacidad de reembolso de QUBIT PHARMACEUTICALS (-44.2 an) se sitúa en el 25% más bajo del sector, lo cual es positivo. Este ratio indica el número de años necesarios para pagar la deuda con flujo de caja. Una capacidad corta refleja deuda controlada y buena generación de efectivo.

Liquidity ratios

El ratio de liquidez se sitúa en 249.36. La empresa tiene 2€ de activos líquidos por cada 1€ de deuda a corto plazo.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

249.363

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-20.455

Liquidity indicators evolution
QUBIT PHARMACEUTICALS

Sector positioning

Ratio de liquidez
249.36 2024
2022
2023
2024
Q1: 141.9
Med: 230.48
Q3: 460.89
Bueno -23 pts over 3 years

En 2024, el ratio de liquidez de QUBIT PHARMACEUTICALS (249.36) se sitúa por encima de la mediana del sector. Este ratio mide la capacidad de cubrir deuda a corto plazo con activos corrientes. Esta posición cómoda ofrece un margen de seguridad apreciable.

Cobertura de intereses
-20.45x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.0x
Q3: 1.04x
Average

En 2024, el cobertura de intereses de QUBIT PHARMACEUTICALS (-20.4x) se sitúa por debajo de la mediana del sector. Este ratio indica cuántas veces el resultado operativo cubre los gastos de intereses. Una mejora fortalecería la posición competitiva.

Working capital requirement (WCR) and payment terms

El fondo de maniobra operativo (FM) mide el desfase temporal de tesorería. Plazo medio de cobro a clientes: 0 días. Plazo proveedores: 43 días. Excelente situación: los proveedores financian 43 días del ciclo operativo. El FM representa 5501 días de ingresos.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

2 862 526 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

43 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

5501 j

WCR and payment terms evolution
QUBIT PHARMACEUTICALS

Positioning of QUBIT PHARMACEUTICALS in its sector

Comparison with sector Conseil en systèmes et logiciels informatiques

Valuation estimate

Based on 215 transactions of similar company sales (all years), the value of QUBIT PHARMACEUTICALS is estimated at 30 067 € (range 16 127€ - 54 922€). The price/revenue ratio is 0.16x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
215 transactions
16k€ 30k€ 54k€
30 067 € Range: 16 127€ - 54 922€
NAF 5 all-time

Valuation method used

Revenue Multiple
187 318 € × 0.16x = 30 067 €
Range: 16 128€ - 54 922€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 215 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Conseil en systèmes et logiciels informatiques)

Compare QUBIT PHARMACEUTICALS with other companies in the same sector:

Voir toutes les statistiques du secteur Conseil en systèmes et logiciels informatiques

Frequently asked questions about QUBIT PHARMACEUTICALS

What is the revenue of QUBIT PHARMACEUTICALS ?

The revenue of QUBIT PHARMACEUTICALS in 2024 is 187 k€.

Is QUBIT PHARMACEUTICALS profitable?

QUBIT PHARMACEUTICALS recorded a net loss in 2024.

Where is the headquarters of QUBIT PHARMACEUTICALS ?

The headquarters of QUBIT PHARMACEUTICALS is located in PARIS (75014), in the department Paris.

Where to find the tax return of QUBIT PHARMACEUTICALS ?

The tax return of QUBIT PHARMACEUTICALS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does QUBIT PHARMACEUTICALS operate?

QUBIT PHARMACEUTICALS operates in the sector Conseil en systèmes et logiciels informatiques (NAF code 62.02A). See the 'Sector positioning' section above to compare the company with its competitors.